logo
Over A Third of US Adults Are Unaware of HPV

Over A Third of US Adults Are Unaware of HPV

Medscape2 days ago
TOPLINE:
Human papillomavirus (HPV) awareness remained critically low across the US between 2017 and 2020, with over one third of adults unaware of HPV and its corresponding vaccine. This was particularly true in Midwestern and Southern states, regions in which HPV-associated cancers are rising, and vaccination rates are suboptimal.
METHODOLOGY:
About 48,000 HPV-associated cancers are diagnosed annually in the US, predominantly in Midwestern and Southern states. Public awareness of HPV and its vaccine is crucial for increasing vaccination rates and preventing these cancers.
Using data from the 2017-2020 Health Information National Trends Survey (HINTS) 5 Cycles 1-4 and 2022 HINTS Cycle 6 in the US, researchers assessed the awareness of HPV, HPV vaccine, and its role in causing cervical and oral cancers among 22,344 respondents (mean age, 49 years; 51.1% women).
Participants responded to questions such as 'Have you ever heard of HPV?' and 'Before today, have you ever heard of the cervical cancer vaccine or HPV shot?' Those who had heard of HPV were asked, 'Do you think HPV can cause oral cancer?' and 'Do you think HPV can cause cervical cancer?' A response of 'no' or 'not sure' indicated lack of awareness about HPV.
TAKEAWAY:
Overall, 34.3% of adults lacked awareness about HPV, whereas 37.6% were unaware of the HPV vaccine.
Among those aware of HPV, 70.8% did not know HPV causes oral cancer, whereas 28.3% were unaware of its link to cervical cancer.
More than 60% of individuals in 45 states and Washington, DC, were unaware that HPV causes oral cancer, whereas unawareness of its link to cervical cancer varied widely (6.9%-57.4%).
Awareness about HPV was lacking in over 40% of adults in seven states, predominantly from the Midwest and the South. Likewise, awareness about HPV vaccine was lacking in more than 40% of adults in 13 states, with nine being from the Midwest and the South.
IN PRACTICE:
'In conclusion, given the importance of timely HPV vaccination and the risk of early-life exposure, there is a critical need to enhance HPV awareness among adolescents, young adults, parents or caregivers, and pediatric and adult healthcare professionals,' the authors of the study wrote.
SOURCE:
This study, led by Ashvita Garg, PhD, MPH, MBBS, Medical University of South Carolina in Charleston, South Carolina, was published online in JAMA Oncology.
LIMITATIONS:
The cross-sectional nature of the data prevented causal inferences, while the ecological nature of the analyses and limited sample sizes for certain states affected the generalizability of findings.
DISCLOSURES:
The research was supported by grants from the National Institute on Minority Health and Health Disparities, the National Library of Medicine, and the National Cancer Institute. One author disclosed receiving personal fees from Merck, grants and nonfinancial support from Stryker, and serving as deputy editor for JAMA Otolaryngology-Head & Neck Surgery. Another author reported receiving personal fees from Value Analytics Labs, outside the submitted work. No other disclosures were reported.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Measles vaccine plea ahead of school term
Measles vaccine plea ahead of school term

Yahoo

time27 minutes ago

  • Yahoo

Measles vaccine plea ahead of school term

Parents are being urged by health officials to make sure their children are vaccinated before the return to school as measles cases still circulate in the West Midlands. Uptake of the measles, mumps and rubella (MMR) jabs by age five is as low as 75.8% in parts of the region, according the UK Health Security Agency (UKHSA) - the World Health Organisation recommends a 95% uptake to prevent outbreaks. It comes after Birmingham saw an outbreak in 2025 with 26 confirmed cases between January and June, government figures showed. Katie Spence, from the UKHSA, described measles as a "nasty virus" that can spread quickly among unvaccinated children and adults in places like schools and nurseries. "It can lead to serious health problems including ear and chest infections, inflammation of the brain, with some children ending up in hospital and being left with permanent disabilities. Tragically, in rare cases, it can even be fatal," she said. "As children under the age of one cannot be vaccinated against measles, it's important siblings are vaccinated to protect little ones and other vulnerable people – including those with weakened immune systems – who are unable to have the MMR vaccine and rely on the rest of us to protect them from measles." She added that if parents are unsure about their child's vaccination record, they can check their Red Book, the NHS app or contact their GP surgery. In 2024, figures from the UKHSA showed 329 of 465 (71%) measles cases across England from October 2023 to February 2024 were in the West Midlands. A GP in the Sparkbrook area of Birmingham said at the time that, in the majority of cases, medics were seeing were in unvaccinated people. The latest measles data from the UKHSA this summer revealed that there have been 674 laboratory-confirmed measles cases reported in England since 1 January, with 145 in 3-31 July. The West Midlands had 34 out of the 674 cases. Follow BBC Birmingham on BBC Sounds, Facebook, X and Instagram. More stories like this Measles vaccination reminder as cases stabilise Health boss tells of 'battle' with anti-vax groups Measles cases continuing to rise Measles warning for parents in East Sussex Related internet links UK Health Security Agency

AI designs antibiotics to fight drug-resistant superbugs
AI designs antibiotics to fight drug-resistant superbugs

Yahoo

time2 hours ago

  • Yahoo

AI designs antibiotics to fight drug-resistant superbugs

An artificial intelligence model designed new antibiotics to fight gonorrhea and mRSA superbugs. The overuse of antibiotics can create resistance, when the drugs kill off all but those bacteria most capable of surviving the treatment. It has led to the rise of some bugs that are all but impossible to treat with existing antibiotics, raising fears that modern medicine and surgery — reliant on antibiotics — could collapse, given that few new antibiotics are produced. The new drugs were designed atom-by-atom using AI, and while they are a long way from the clinic, researchers hoped they could create a new pipeline for drugs. AI is rapidly transforming drug development and biology, allowing scientists to better predict how molecules behave in the body. Solve the daily Crossword

Cancer vaccine shows promise in preventing recurrence of pancreatic, colorectal tumors
Cancer vaccine shows promise in preventing recurrence of pancreatic, colorectal tumors

Fox News

time3 hours ago

  • Fox News

Cancer vaccine shows promise in preventing recurrence of pancreatic, colorectal tumors

An experimental cancer vaccine has shown promise in keeping certain cancers from coming back. In a phase 1 clinical trial led in part by the UCLA Health Jonsson Comprehensive Cancer Center, researchers tested the vaccine (ELI-002 2P) with 25 patients who had been treated for pancreatic and colorectal cancer. The patients had all undergone surgery to remove tumors and showed "signs of minimal residual disease" or traces of DNA, putting them at a high risk of recurrence, according to a UCLA press release. More than 80% of pancreatic cancer patients experience recurrence of the disease after surgery, research shows — and for 40% to 50%, this happens within the first year. For colorectal cancer, the recurrence rate is between 30% and 50% and is most likely to occur within the first two years after surgery. Mutations in the KRAS gene are responsible for half of colorectal cancers and more than 90% of pancreatic cancers. The vaccine, which targets those mutations, was given via a series of injections to activate an immune response in the lymph nodes. A majority (21 out of 25) of the patients generated "KRAS-specific T cells," which indicates a stronger immune response. The ones with higher T-cell responses showed a longer relapse-free survival compared to those with lower responses, the researchers found. For three colorectal cancer patients and three pancreatic cancer patients, the vaccine appeared to remove all disease biomarkers. Among the patients who showed the strongest immune response, a majority were still cancer-free nearly 20 months after receiving the vaccine. The findings were published in Nature Medicine. "This is an exciting advance for patients with KRAS-driven cancers, particularly pancreatic cancer, where recurrence after standard treatment is almost a given and effective therapies are limited," said first author of the study, Zev Wainberg, M.D., professor of medicine at the David Geffen School of Medicine at UCLA and researcher in the UCLA Health Jonsson Comprehensive Cancer Center, in the release. "We observed that patients who developed strong immune responses to the vaccine remained disease-free and survived for much longer than expected." "The new cancer vaccine from UCLA is very promising as a major tool against these cancers." In another finding, 67% of the patients in the trial showed immune responses to "additional tumor-associated mutations," indicating that the vaccine could be used to suppress "broader anti-tumor activity." One of the benefits of ELI-002 2P, according to the researchers, is that it's considered "off-the-shelf," which means it's a mass-produced, standardized vaccine that doesn't have to be personalized for each individual patient. "This study shows that the ELI-002 2P vaccine can safely and effectively train the immune system to recognize and fight cancer-driving mutations," Wainberg said. "It offers a promising approach to generating precise and durable immune responses without the complexity or cost of fully personalized vaccines." The team has already finished enrolling participants for a phase 2 study that will test ELI-002 7P, the next iteration of the vaccine that will target a "broader set" of KRAS mutations, the release stated. The study was sponsored and funded by Elicio Therapeutics, the Massachusetts company that developed the vaccine. It was conducted in conjunction with the MD Anderson Cancer Center and the Memorial Sloan Kettering Cancer Center. Dr. Marc Siegel, Fox News senior medical analyst, was not involved in the study but commented that targeted therapies are becoming increasingly important tools in the fight against cancer. "Solid tumors, especially pancreatic, can be difficult to treat because they are not as mutagenic (capable of inducing or causing mutations) as hematological malignancies (blood cancers) or melanoma, for example, so they don't have as many ready targets for immunotherapy," he told Fox News Digital. For more Health articles, visit "The new cancer vaccine from UCLA is very promising as a major tool against these cancers, as it 'programs' the immune system to target these mutations and has been shown in the NATURE study to elicit a strong clinical response."

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store